16.05.08: Phase III Asia-Pacific Study:

bayer.com     May 16, 2008            

Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent Trial Results Confirm Efficacy for Population Most Affected by the Disease Berlin, May 16, 2008 - Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies